Page 4 - Nifty Pharma

Here's what the charts suggest for Nifty Realty, Media, Pharma indices

According to Ravi Nathani, an independent technical analyst, one should look to book profits in Nifty Realty either at current levels or on rally.

Can the rally in Nifty Realty index sustain? Here's what charts suggest

The Nifty Realty Index could face stiff resistance in the range of 445 to 457 levels.

Chart check: Buy the dips in Nifty Pharma, Sell the rallies in Nifty FMCG

The near-term trend is displaying a bullish bias for the Nifty Pharma index

Traders can adopt 'buy-on-dips' strategy for Nifty Media: Ravi Nathani

According to the technical analyst, the Nifty Media Index is currently displaying a range-bound pattern, with fluctuations occurring within a prescribed range

Charts suggest near-term upside for pharma, oil & gas shares: Ravi Nathani

According to the technical analyst, he remains bullish on Nifty Pharma, and Nifty Oil & Gas indices

Nifty Pharma index hits 2-year low; Cipla, Divis, Laurus Labs at 52-wk lows

Analysts said the pace of US FDA inspections has again picked-up in the last few months post Covid, and they have seen increased incidents with 483 observations and adverse outcomes

Charts signal bearish trend for Nifty Pharma in near-term: Ravi Nathani

According to the technical analyst, traders must adopt 'sell-on-rise' strategy for Nifty Pharma, Nifty Energy, and Nifty Midcap 100 indices

Analysts turn cautious on Cipla as US FDA action delays key US launches

Analysts believe that some of the recent observations from the US FDA are critical in nature and could lead to a potential Official Action Indicated (OAI) classification for the Indore plant

Nifty IT, Realty indices look bullish on chart: Ravi Nathani

The technical analyst also expects a pullback in the Nifty Pharma index.

Ravi Nathani recommends to focus on realty, pharma shares on dips

The technical analyst also advices to avoid media stocks for now, as the Nifty Media index could side to 1,631 level.

Nifty Pharma dips to 7-mth low; bears may gain control if breaks 52-wk low

Barring Sun Pharmaceutical Industries, which is anticipated to rally up to 10 per cent; other stocks indicate weak bias, as per technical charts

Here's why Ravi Nathani is bullish on realty, pharma shares over near-term

According to the technical analyst, charts suggest bullish trend for Nifty Pharma, Nifty Realty, and Nifty Media indices

Stay selective on defensives amid current market volatility: Analysts

Given the uncertainty on how the market trajectory may play out ahead, analysts believe investors can rotate allocation from high beta stocks to defensive plays albeit selectively

Here's why Ravi Nathani is bullish on Nifty 50 index in the near-term

Traders must adopt a bullish stance on the market as the Nifty 50 index closed above 17,870, indicating that bulls are likely to be stronger than bears in the near-term, says Ravi Nathani

Look to accumulate pharma, media shares near support levels: Ravi Nathani

According to the technical analyst, the Nifty Pharma index is likely to get support around 11,981 level.

Ravi Nathani recommends to wait for correction to complete in these sectors

According to the technical analyst, the Nifty Realty, Pharma and Media index and its constituents can be accumulated once the corrective move is over.

Pharma, Energy, Commodities indices look bearish on charts: Ravi Nathani

According to the technical analyst, the Nifty Energy index can drop to 24,239, and the Pharma to 12,100.

Trend looks bullish on Nifty Pharma, Media indices, says Ravi Nathani

According to the technical analyst, the Nifty Pharma index can rally up to 13,250 level, while the Media index can surge to 2,080 level.

Tech view: Check key levels on Sensex, Nifty as trend remains indecisive

The overall sentiment towards the market has remained indecisive and ambiguous, with market participants waiting for a clear direction

Pharma stocks upbeat amid Covid-19 scare; Divi's, Lupin can gain up to 10%

Technically, the Nifty Pharma index needs to immediate hurdle at 13,500, for further upside to 14,250.